您的位置: 专家智库 > >

国家自然科学基金(81173216)

作品数:4 被引量:33H指数:4
相关作者:张玉佩杨钦河徐拥建闫海震刘益臻更多>>
相关机构:暨南大学暨南大学附属第一医院更多>>
发文基金:国家自然科学基金更多>>
相关领域:医药卫生更多>>

文献类型

  • 4篇中文期刊文章

领域

  • 4篇医药卫生

主题

  • 3篇疏肝
  • 3篇疏肝健脾
  • 3篇疏肝健脾方
  • 3篇疏肝健脾方药
  • 3篇健脾
  • 3篇健脾方
  • 3篇方药
  • 3篇SREBP-...
  • 2篇脂肪
  • 2篇脂肪性
  • 2篇脂肪性肝病
  • 2篇鼠肝
  • 2篇鼠肝细胞
  • 2篇细胞
  • 2篇酒精
  • 2篇酒精性
  • 2篇酒精性脂肪性...
  • 2篇固醇
  • 2篇固醇调节元件...
  • 2篇固醇调节元件...

机构

  • 3篇暨南大学
  • 2篇暨南大学附属...

作者

  • 3篇徐拥建
  • 3篇杨钦河
  • 3篇张玉佩
  • 2篇金玲
  • 2篇闫海震
  • 2篇韩莉
  • 2篇刘益臻
  • 1篇张金文
  • 1篇林春梅
  • 1篇黄进
  • 1篇杨雪松
  • 1篇龚享文

传媒

  • 1篇中国中西医结...
  • 1篇中成药
  • 1篇中药材
  • 1篇Chines...

年份

  • 4篇2014
4 条 记 录,以下是 1-4
排序方式:
疏肝健脾方药对LXRα/FAS信号通路介导非酒精性脂肪性肝病大鼠肝细胞脂肪沉积的影响被引量:8
2014年
目的探讨疏肝健脾方药对LXRα/FAS信号通路介导非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)大鼠肝细胞脂肪沉积的影响。方法选用SPF级雄性SD大鼠75只,共分5组,每组15只,分别为:正常组,模型组,疏肝组,健脾组及合方组;除正常组,其余均各组采用高脂饮食复制NAFLD大鼠模型,给药各组分别给予疏肝方(柴胡疏肝散)、健脾方(参苓白术散)、合方(柴胡疏肝散和参苓白术散合方)进行干预,采用全自动生化分析肝脂改变,分离出肝细胞,Typan blue染色和流式细胞术(FCM)对肝细胞的活性及纯度进行鉴定。采用实时定量PCR法检测肝细胞LXRαmRNA、FAS mRNA的表达,采用Western blot法检测LXRα、FAS蛋白在肝细胞中的表达。结果 (1)油红O染色后模型组的NAFLD大鼠病理结构显示肝细胞肿胀,细胞核位于细胞边缘,细胞浆内可见大小不等的小空泡,部分肝细胞小空泡融合成大泡等特征性改变,提示成功建立高脂饮食诱导NAFLD大鼠实验动物模型。各组中药对NAFLD病理结构改变均有不同程度的修复作用,尤以疏肝组明显。(2)与正常组比较,模型组肝细胞LXRα、FAS基因及蛋白的表达水平均明显升高(P<0.01);与模型组比较,健脾方和疏肝方组的表达水平下调明显(P<0.01,P<0.05)。结论 LXRα/FAS通路是介导NAFLD脂质平衡代谢紊乱重要的信号通路,疏肝健脾方药能够调控肝细胞LXRα/FAS通路使NAFLD大鼠肝细胞脂肪沉积趋于恢复,这可能是疏肝健脾方药抗实验性大鼠脂肪肝的作用机制之一。
龚享文杨钦河闫海震张玉佩黄进徐拥建张金文林春梅
关键词:非酒精性脂肪性肝病疏肝健脾方药肝细胞
疏肝健脾方药对NAFLD大鼠肝细胞SREBP-1c、SCD-1 mRNA及蛋白表达的影响被引量:17
2014年
目的:观察疏肝健脾方药对非酒精性脂肪性肝病(NAFLD)大鼠肝细胞SREBP-1c、SCD-1 mRNA及蛋白表达的影响,探讨其防治NAFLD的可能机制。方法:雄性SD大鼠75只随机分为正常对照组、模型组、疏肝组(柴胡疏肝散9.6 g/kg)、健脾组(参苓白术散30 g/kg)、合方组(柴胡疏肝散和参苓白术散合方39.6 g/kg),每组15只。采用高脂饲料喂养复制大鼠NAFLD模型。8 w后每组随机选取9只检测肝功及肝组织TC、TG,观察肝组织病理形态改变;同时每组取6只采用离体循环灌注Ⅳ型胶原酶法提取肝细胞,Q-PCR及Western Blot法检测肝细胞SREBP-1c、SCD-1 mRNA及蛋白表达。结果:与模型组比较,各药物干预组肝细胞SREBP-1c、SCD-1 mRNA及蛋白表达水平均有不同程度的下调(P<0.05或P<0.01),同时肝脂及病理学改变也较模型组有不同程度改善,以疏肝组作用最为显著(P<0.05)。各药物干预组组间比较,疏肝组大鼠肝细胞SREBP-1c、SCD-1 mRNA表达水平显著低于健脾组(P<0.05),而蛋白表达比较无统计学意义。结论:疏肝健脾方药可能通过抑制肝细胞SREBP-1c/SCD-1信号通路的激活,进而下调肝脏TC、TG合成,发挥防治NAFLD的作用。SREBP-1c、SCD-1 mRNA及蛋白可能是疏肝健脾方药抗NAFLD的有效作用靶点。
徐拥建杨钦河韩莉张玉佩刘益臻金玲闫海震
关键词:疏肝健脾方药固醇调节元件结合蛋白-1C肝细胞
疏肝健脾方药对非酒精性脂肪性肝病大鼠Kupffer细胞SREBP-1c信号通路相关基因及蛋白表达的影响被引量:7
2014年
目的观察疏肝健脾方药对非酒精性脂肪性肝病(NAFLD)大鼠Kupffer细胞固醇调节元件结合蛋白-1c(SREBP-1c)信号通路相关基因及蛋白表达的影响及可能的机制。方法采用高脂饲料喂养复制大鼠NAFLD模型,各药物干预组灌饲相应的疏肝健脾方药,8周后检测血液常规生化指标,观察肝组织病理形态改变;采用离体循环灌注Ⅳ型胶原酶法提取肝脏Kupffer细胞,Q-PCR及Western blot法检测Kupffer细胞SREBP-1c、硬脂酰辅酶A去饱合酶-1(SCD-1)mRNA及蛋白表达水平。结果模型组大鼠肝脏脂肪蓄积;血脂及Kupffer细胞SREBP-1c、SCD-1mRNA及蛋白表达水平较正常组均显著升高(P<0.01);各药物干预组Kupffer细胞SREBP-1c、SCD-1 mRNA及蛋白表达水平均有不同程度的下调,同时血脂及病理学改变也较模型组有不同程度的改善,以疏肝组作用最为显著(P<0.01)。结论疏肝健脾方药可能是通过抑制Kupffer细胞SREBP-1c/SCD-1信号通路激活,下调血清总胆固醇、甘油三酯合成,减少肝脏脂质沉积,发挥抗NAFLD作用。可推测SREBP-1c、SCD-1 mRNA及蛋白可能是疏肝健脾方药抗NAFLD的有效作用靶点。
韩莉杨钦河张玉佩徐拥建刘益臻杨雪松金玲
关键词:疏肝健脾方药非酒精性脂肪性肝病固醇调节元件结合蛋白-1CKUPFFER细胞
Effects of Soothing Liver and Invigorating Spleen Recipe on Lipid Metabolism Disorders in Kupffer Cells of NAFLD Rats by LXRα/SREBP-1c Signal Pathway被引量:8
2014年
Objective To investigate the mechanism of lipid metabolism disorders in Kupffer cells (KCs) of non-alcoholic fatty liver disease (NAFLD) rats mediated by LXRα-SREBP-lc pathway and the interference of soothing liver and invigorating spleen recipe (SLISR) on it. Methods SD male rats were randomly divided into five groups: normal, model, soothing liver recipe (SLR), invigorating spleen recipe (ISR), and soothing liver and invigorating spleen recipe (SLISR) groups. The rats in treatment groups were administered for 8 weeks. The liver tissue was stained with H&E and oil red O. The levels of hepatic lipid and blood lipid were measured by biochemical analyzer. KCs were isolated from the livers of rats to evaluate the expression of LXRα, SREBP-1 C, and FAS mRNA by real-time fluorescence quantitative PCR tests; LXRα, SREBP-1C, and FAS proteins were measured by Western blotting. Results The H&E and oil red O staining results showed that the model rats successfully reproduced typical pathogenetic and histopathological features of NAFLD. The levels of hepatic lipid and blood lipid in the model rats were dramatically increased. Compared with the model group, the values of hepatic lipid and blood lipid in the treatment groups were significantly ameliorated (P〈 0.05, 0.01 ). The yields of purified KCs from each rat were 2×10^7-3×10^7. The viability of KCs was higher than 95%, with the purity over 90.18%. Compared with the model group, the expression of LXRα, SREBP-1C, and FAS mRNA and proteins was decreased in all treatment groups, especially in the SLR group (P〈 0.05). Conclusion SLISR may protect liver against injury included by lipid metabolism disorders in KCs through LXRα/ SREBP-1 c signaling pathway, which may be an important mechanism for the prevention and treatment of NAFLD.
Xiang-wen GongLi-HanQin-he YangHai-zhen YanYu-pei ZhangYuan-yuan LiYong-jian XuHong WangJin-wen ZhangChun-mei Lin
共1页<1>
聚类工具0